Drug

AbbVie's RINVOQ Wins NMPA Approval for Severe Alopecia Areata – Ninth Indication in China Three Months After EU Clearance
AbbVieNYSE: ABBV

AbbVie’s RINVOQ Wins NMPA Approval for Severe Alopecia Areata – Ninth Indication in China Three Months After EU Clearance

AbbVie Inc. (NYSE: ABBV) announced that China's National Medical Products Administration (NMPA) has approved RINVOQ (upadacitinib extended‑release tablets, 15 mg and 30 mg, once daily) for the treatment of adults…

CSPC Pharmaceutical's Trispecific Antibody SYS6088 Wins NMPA Clinical Trial Approval – PD‑1/VEGFA/CTLA‑4 Candidate Targets Advanced and Metastatic Solid Tumors

CSPC Pharmaceutical’s Trispecific Antibody SYS6088 Wins NMPA Clinical Trial Approval – PD‑1/VEGFA/CTLA‑4 Candidate Targets Advanced and Metastatic Solid Tumors

Qilu Pharmaceutical's QLS2401 Wins CDE Clinical Trial Approval – Trispecific PSMA/STEAP1/CD3 T‑Cell Engager Targets Metastatic Castration‑Resistant Prostate Cancer

Qilu Pharmaceutical’s QLS2401 Wins CDE Clinical Trial Approval – Trispecific PSMA/STEAP1/CD3 T‑Cell Engager Targets Metastatic Castration‑Resistant Prostate Cancer

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Clinical trial resultsHighTide Therapeutics

HighTide Therapeutics Reports Positive Phase IIb CENTRICITY Data for HTD1801 in MASH Patients

J&J Darzalex Faspro Gets NMPA Approval for Transplant-Eligible Myeloma Patients
CancerJ&J

J&J Darzalex Faspro Gets NMPA Approval for Transplant-Eligible Myeloma Patients

Everest Medicines Files Velsipity for Ulcerative Colitis in China
Everest MedicinesHKG: 1952

Everest Medicines Files Velsipity for Ulcerative Colitis in China

Keytruda Wins 20th China Approval for Endometrial Cancer in First-Line Setting
CancerMerck Sharp & Dohme

Keytruda Wins 20th China Approval for Endometrial Cancer in First-Line Setting

Show More